Braidwell LP Acquires Shares of 247,750 BioNTech SE (NASDAQ:BNTX)

Braidwell LP acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 247,750 shares of the company’s stock, valued at approximately $29,425,000. Braidwell LP owned about 0.10% of BioNTech as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Planning Capital Management Corp increased its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. increased its stake in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares in the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of BioNTech in the 3rd quarter valued at about $210,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 1.8 %

Shares of NASDAQ BNTX opened at $120.72 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The business’s 50 day moving average is $113.52 and its two-hundred day moving average is $98.35.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the company earned $0.73 earnings per share. The company’s revenue was up 38.9% on a year-over-year basis. As a group, equities research analysts predict that BioNTech SE will post -3.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Berenberg Bank began coverage on BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $138.67.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.